Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.
2.

The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples.

O'Neil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF.

J Urol. 2016 Feb;195(2):321-9. doi: 10.1016/j.juro.2015.08.092. Epub 2015 Sep 3.

PMID:
26343985
3.

The current trend of administering a patient-generated index in the oncological setting: a systematic review.

Tang JA, Oh T, Scheer JK, Parsa AT.

Oncol Rev. 2014 Jun 30;8(1):245. doi: 10.4081/oncol.2014.245. eCollection 2014 Mar 17. Review.

4.

Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomes.

Hudson SV, O'Malley DM, Miller SM.

Patient Relat Outcome Meas. 2015 Mar 19;6:75-90. doi: 10.2147/PROM.S49588. eCollection 2015. Review.

5.

Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy.

Dirksen SR, Belyea MJ, Wong W, Epstein DR.

Cancer Nurs. 2016 Jan-Feb;39(1):3-11. doi: 10.1097/NCC.0000000000000236.

PMID:
25730597
6.

Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.

Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, Watkins-Bruner D, Reeve BB, Sandler HM.

J Natl Cancer Inst. 2014 Jul 8;106(7). pii: dju132. doi: 10.1093/jnci/dju132. Print 2014 Jul. Review.

7.

Failure to address potential bias in non-randomised controlled clinical trials may cause lack of evidence on patient-reported outcomes: a method study.

Peinemann F, Labeit AM, Thielscher C, Pinkawa M.

BMJ Open. 2014 Jun 4;4(6):e004720. doi: 10.1136/bmjopen-2013-004720.

8.

Concept and viability of androgen annihilation for advanced prostate cancer.

Mohler JL.

Cancer. 2014 Sep 1;120(17):2628-37. doi: 10.1002/cncr.28675. Epub 2014 Apr 25. Review.

9.

Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments.

Schmidt S, Garin O, Pardo Y, Valderas JM, Alonso J, Rebollo P, Rajmil L, Garcia-Forero C, Ferrer M; EMPRO Group.

Qual Life Res. 2014 Oct;23(8):2169-81. doi: 10.1007/s11136-014-0678-8. Epub 2014 Apr 19.

10.

Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β2.

Ting HJ, Deep G, Jain AK, Cimic A, Sirintrapun J, Romero LM, Cramer SD, Agarwal C, Agarwal R.

Mol Carcinog. 2015 Sep;54(9):730-41. doi: 10.1002/mc.22135. Epub 2014 Feb 24.

PMID:
24615813
12.

The strategies to control prostate cancer by chemoprevention approaches.

Ting H, Deep G, Agarwal C, Agarwal R.

Mutat Res. 2014 Feb;760:1-15. doi: 10.1016/j.mrfmmm.2013.12.003. Epub 2014 Jan 2. Review.

13.

Potency preservation following stereotactic body radiation therapy for prostate cancer.

Obayomi-Davies O, Chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, Yung TM, Lei S, Batipps GP, Pahira J, McGeagh KG, Collins BT, Kowalczyk K, Bandi G, Kumar D, Suy S, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Nov 1;8:256. doi: 10.1186/1748-717X-8-256.

14.

Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer.

Shinohara N, Maruyama S, Shimizu S, Nishioka K, Abe T, C-Hatanaka K, Oba K, Nonomura K, Shirato H.

J Radiat Res. 2013 Nov 1;54(6):1095-101. doi: 10.1093/jrr/rrt049. Epub 2013 May 9.

15.

Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Ting H, Deep G, Agarwal R.

AAPS J. 2013 Jul;15(3):707-16. doi: 10.1208/s12248-013-9486-2. Epub 2013 Apr 16. Review.

16.

Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.

Ghadjar P, Jackson A, Spratt DE, Oh JH, Munck af Rosenschöld P, Kollmeier M, Yorke E, Hunt M, Deasy JO, Zelefsky MJ.

Eur Urol. 2013 Dec;64(6):931-8. doi: 10.1016/j.eururo.2013.02.001. Epub 2013 Feb 14.

17.
18.

Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.

Parthan A, Pruttivarasin N, Davies D, Taylor DC, Pawar V, Bijlani A, Lich KH, Chen RC.

Front Oncol. 2012 Aug 20;2:81. doi: 10.3389/fonc.2012.00081. eCollection 2012.

19.

Trajectories and predictors of symptom occurrence, severity, and distress in prostate cancer patients undergoing radiation therapy.

Knapp K, Cooper B, Koetters T, Cataldo J, Dhruva A, Paul SM, West C, Aouizerat BE, Miaskowski C.

J Pain Symptom Manage. 2012 Oct;44(4):486-507. doi: 10.1016/j.jpainsymman.2011.10.020. Epub 2012 Jul 7.

20.

Proton Therapy: Ever Shifting Sands and the Opportunities and Obligations within.

Hill-Kayser CE, Both S, Tochner Z.

Front Oncol. 2011 Sep 6;1:24. doi: 10.3389/fonc.2011.00024. eCollection 2011.

Items per page

Supplemental Content

Write to the Help Desk